Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
Clot Retraction and Fibrinolysis01:16

Clot Retraction and Fibrinolysis

After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Extrinsic and Intrinsic Pathways of Hemostasis01:20

Extrinsic and Intrinsic Pathways of Hemostasis

Blood clotting or coagulation involves extrinsic and intrinsic pathways, which ultimately merge into the common pathway, forming a fibrin clot.
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which forms a...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A different alternative to warfarin?

Blood advances·2026
Same author

The first clotting factor is also the last.

Blood·2026
Same author

Platelet Polyphosphate Signals Through NFκB to Induce Myofibroblast Differentiation.

Biomolecules·2025
Same author

Cryo-EM structure of the tissue factor/factor VIIa complex with a factor X mimetic reveals a novel allosteric mechanism.

Blood·2025
Same author

ECMO-induced coagulopathy: strategic initiatives for research and clinical practice (a workshop report of the NHLBI).

Blood vessels, thrombosis & hemostasis·2025
Same author

Crystal structure of coagulation factor XII N-terminal domains 1-5.

Acta crystallographica. Section D, Structural biology·2025
Same journal

Exploring the Role of Hypusine Signaling in Vascular Smooth Muscle Cells for Mitigating Restenosis in Coronary Artery Disease.

Arteriosclerosis, thrombosis, and vascular biology·2026
Same journal

Circulating Extracellular Mitochondria Perpetuate Endothelial Damage via Cardiolipin-Mediated Mitophagic Overload.

Arteriosclerosis, thrombosis, and vascular biology·2026
Same journal

Myeloid Cell-Specific Deletion of LGR4 Suppresses Atherosclerotic Lesion Formation.

Arteriosclerosis, thrombosis, and vascular biology·2026
Same journal

Building Resilience in Academic Science and Medicine.

Arteriosclerosis, thrombosis, and vascular biology·2026
Same journal

Endothelial Continuum and Capillary Specialization in Pulmonary Vascular Development.

Arteriosclerosis, thrombosis, and vascular biology·2026
Same journal

Systematic Review and Meta-Analysis Examining the Effect of Upregulation and Inhibition of Proprotein Convertase Subtilisin/Kexin Type 9 in Mouse Models of Abdominal Aortic Aneurysm.

Arteriosclerosis, thrombosis, and vascular biology·2026
See all related articles

Related Experiment Video

Updated: May 10, 2026

Tail Vein Transection Bleeding Model in Fully Anesthetized Hemophilia A Mice
08:13

Tail Vein Transection Bleeding Model in Fully Anesthetized Hemophilia A Mice

Published on: September 30, 2021

Targeting factor XI to prevent thrombosis

James H Morrissey

    Arteriosclerosis, Thrombosis, and Vascular Biology
    |June 15, 2013
    PubMed
    Summary

    No abstract available in PubMed .

    Keywords:
    animal modelsantisense oligonucleotidesfactor XIthrombosis

    More Related Videos

    Helical Organization of Blood Coagulation Factor VIII on Lipid Nanotubes
    12:24

    Helical Organization of Blood Coagulation Factor VIII on Lipid Nanotubes

    Published on: June 3, 2014

    Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay
    13:08

    Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay

    Published on: September 9, 2012

    Related Experiment Videos

    Last Updated: May 10, 2026

    Tail Vein Transection Bleeding Model in Fully Anesthetized Hemophilia A Mice
    08:13

    Tail Vein Transection Bleeding Model in Fully Anesthetized Hemophilia A Mice

    Published on: September 30, 2021

    Helical Organization of Blood Coagulation Factor VIII on Lipid Nanotubes
    12:24

    Helical Organization of Blood Coagulation Factor VIII on Lipid Nanotubes

    Published on: June 3, 2014

    Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay
    13:08

    Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay

    Published on: September 9, 2012